Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.

J ChemotherAug 5, 2025 (epub)

Xing Gong, Weiwei Yan, Feng Zhang et al.

✦ AI-curated · Sources linked

Case in brief

A 38-year-old man presented with persistent dry cough, generalized lymphadenopathy, and fatigue, with elevated serum IgG4. Inguinal lymph node biopsy showed plasma cell-type multicentric Castleman disease, including atrophic lymphoid follicles and marked plasma cell infiltration. Immunostaining found more than 50 IgG4-positive plasma cells per high-power field and an IgG4/IgG ratio of 40%, supporting idiopathic plasmacytic lymphadenopathy subtype of iMCD. Following a siltuximab-based regimen and radiotherapy, he achieved partial remission.

What made this case unusual

The iMCD-IPL presentation had elevated IgG4 and tissue findings resembling IgG4-related disease, creating diagnostic overlap between these systemic immune-mediated disorders.

Diagnostic / clinical pearl

Elevated serum IgG4 and abundant IgG4-positive cells in a lymph node can occur in iMCD-IPL; interpret these findings alongside the broader histopathology rather than assuming IgG4-related disease.

Source

Published in J Chemother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.